Northland Capital Markets upgraded ResMed (NYSE: RMD) from Underperform to Market Perform with a price target of $80.00.Analyst Suraj Kalia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE